Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry. Please send the good word—or the bad—from your shop to Darren Incorvaia, Marissa Russo or Donavyn Coffey, and it will be featured here at the end of each week.
Teva bids adieu to R&D head Eric Hughes
Teva Pharmaceuticals
Teva’s R&D chief Eric Hughes, M.D., Ph.D., has resigned one week after the company showcased its push to grow its innovative medicines business.
Hughes joined Teva in 2022 as executive vice president, global R&D, and chief medical officer. This week, the executive told Teva he intended to resign and accept an offer outside the company, details of which have yet to emerge. Hughes has stepped down but will assist Teva over the next few months to smooth the transition.
Teva named David Gardiner, M.D., its current head of innovative medicines and clinical development, as transition lead for R&D.
Gardiner, who will report to Teva CEO Richard Francis, will serve as transition lead until Teva names a permanent successor. Teva added that it has begun looking for Hughes’ replacement. Story
White House pulls FDA commissioner nomination on eve of vote
FDA
The White House pulled the nomination for Heidi Overton, M.D., Ph.D., to lead the FDA just hours before the Senate was scheduled to vote on her confirmation as the agency's next commissioner.
The move came as a little surprise after Overton’s confirmation hearing before the Senate Health, Education, Labor and Pensions (HELP) Committee drew contention. In September, the HELP committee questioned Overton in a hearing marked by tightrope-walking on issues like vaccines, abortions, flavored vapes and whether or not President Donald Trump is capable of being wrong.
As support for Overton looked thin, Republicans were discussing Senator Roger Marshall, a Kansas Republican, as a potential replacement, although the White House is reportedly not considering the choice.
The move leaves the leadership vacuum at the top of the FDA open following the departure of former agency chief Marty Makary, M.D., in May. Story
Cunningham cuts Quanterix leadership short
Quanterix
After just 10 months at the helm of biomarker detection-focused diagnostics firm Quanterix, president and CEO Everett Cunningham is seeing his way out.
Cunningham, who came to Quanterix fresh off Illumina’s COO post this January, is leaving for “another opportunity,” according to a statement from the company this week. In his absence, Jim Gute, Quanterix’s chief commercial officer as of August, will act as interim leader while the life sciences company embarks on another CEO search. Quanterix said it will consider internal and external candidates for the position.
Back when Cunningham was first appointed, some analysts forecasted a challenging road ahead. Leerink analysts said they “remained cautious” about the company under Cunningham’s leadership and said "transformation at [Quanterix] remains a significant lift for new leadership."
Cunningham said of his time leading the company, “Leading Quanterix has been a privilege, and I am proud of the progress we made.” Story
> Cancer biotech Relmada Therapeutics tapped Ferring Pharma alum and uro-oncology expert Jørn Skibsted Jakobsen, M.D., Ph.D., as its new Chief Development Officer. Jakobsen will help lead development of Relmada’s investigational bladder cancer treatment NDV-01. Release
> San Diego-based 858 Therapeutics appointed Srini Ramanathan, Ph.D., as its new CEO. Ramanathan will captain the oncology biotech as it advances its lead PARG inhibitor ETX-19477 to clinical trials for solid tumors. Release
> Parker Moss will lead Laverock Therapeutics as its new CEO, steering the biotech as it transitions to clinical-stage and plans to launch a Series A funding round in 2027. Release
> After spending nearly a decade with PhRMA, Robert Zirkelbach will be leaving at the end of the month. Zirkelbach noted in a LinkedIn post that his position as chief public affairs officer has been eliminated with the new leadership transition, under which former House majority leader Eric Cantor has stepped up as the trade organization's new CEO. LinkedIn
>Octant appointed Eddy Anglade, M.D., a Tenpoint, Janssen and Astellas alum, as its first chief medical officer. Release
> Lantern Pharma elevated its chief financial officer, David Margrave, to interim CEO as the AI precision oncology biotech looks for a permanent replacement following the resignation this week of Panna Sharma. Release
> NervGen is bringing aboard Sam Jackson, M.D., as its chief medical officer to lead late-stage development of the company's first-in-class neuroreparative treatment for spinal cord injuries. Release
> Novartis alum Scott Howell, M.D., joined GOA Therapeutics as its new chief commercial officer. The biotech is gearing up for the potential commercialization of GOA26, its lead drug candidate to rapidly lower blood alcohol content for use in emergency settings. Release
> Farah Ali, M.D., is joining the C-suite at ProKidney as chief medical officer. Ali will oversee the cell-therapy company’s pivotal phase 3 in advanced chronic kidney disease. Release